Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Up 0.15% from its 2025 settlement low of $72.62 hit Wednesday, Jan. 29, 2025 --Off 49.94% from its record high of $145.29 hit Thursday, July 3, 2008 --Month-to-date it is up 1.41% --Year-to-date it is ...

IBM Share Price Surges 12.9% after posting better-than-expected earnings, driven by strong AI and cloud growth. Can the rally ...

Viking Therapeutics VKTX is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...

The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Eli Lilly & Co. (LLY) is rebounding from Friday's sales disappointment, finding support at $722 and set for another uptrend.

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s ...